Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Lewy body dementia, Alzheimers disease, and control anterior cingulate cortex tissue samples

PROVIDER: PRJNA1023207 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26253900_1.fastq.gz	Fastqsanger.gz
	SRR26253900_2.fastq.gz	Fastqsanger.gz
	SRR26254000_1.fastq.gz	Fastqsanger.gz
	SRR26254000_2.fastq.gz	Fastqsanger.gz
	SRR26254100_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1218

Similar Datasets

Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in lewy body diseases

Project description:Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) are three clinically, genetically and neuropathologically overlapping neurodegenerative diseases collectively known as the Lewy body diseases (LBDs). A variety of molecular mechanisms have been implicated in PD pathogenesis, but the mechanisms underlying PDD and DLB remain largely unknown, a knowledge gap that presents an impediment to the discovery of diseasemodifying therapies. Transcriptomic profiling can contribute to addressing this gap, but remains limited in the LBDs. Here, we applied paired bulk-tissue and single-nucleus RNA-sequencing to anterior cingulate cortex samples derived from 28 individuals, including healthy controls, PD, PDD and DLB cases (n = 7 per group), to transcriptomically profile the LBDs. Using this approach, we (i) found transcriptional alterations in multiple cell types across the LBDs; (ii) discovered evidence for widespread dysregulation of RNA splicing, particularly in PDD and DLB; (iii) identified potential splicing factors, with links to other dementia-related neurodegenerative diseases, coordinating this dysregulation; and (iv) identified transcriptomic commonalities and distinctions between the LBDs that inform understanding of the relationships between these three clinical disorders. Together, these findings have important implications for the design of RNA-targeted therapies for these diseases and highlight a potential molecular “window” of therapeutic opportunity between the initial onset of PD and subsequent development of Lewy body dementia.

2021-08-15 | GSE178146 | GEO

90acec62-af7b-4883-9110-c0ada6186172 - samples

Project description:Profiling of 24 human anterior cingulate cortex samples by bulk-tissue RNA-sequencing. Samples were derived from 5 non-neurological control individuals and 19 individuals with Lewy body disease (ParkinsonÃ¢Â€Â™s disease = 7 individuals; ParkinsonÃ¢Â€Â™s disease with dementia = 6 individuals; dementia with Lewy bodies = 6 individuals). Paired-end FASTQ files for each of the human samples are provided and are denoted by the suffixes R1 (read 1) and R3 (read 2). Fastp (v 0.20.0), a fast all-in-one FASTQ pre-processor, was used for adapter trimming, read filtering and base correction. Fastp default settings were used for quality filtering and base correction. Further details on parameters used are available here: https://github.com/RHReynolds/RNAseqProcessing/blob/master/QC/prealignmentQC_fastp_PEadapters.R.

| EGAD00001007698 | EGA

human gut metagenome

Project description:Lewy Body Dementia Microbiome

| PRJNA962059 | ENA

human metagenome

Project description:Microbiota for Dementia with Lewy body

| PRJDB11085 | ENA

Bulk-tissue RNA-sequencing of anterior cingulate cortex samples derived from Lewy body disease patients

Project description:ParkinsonÃ¢Â€Â™s disease (PD), ParkinsonÃ¢Â€Â™s disease with dementia (PDD) and dementia with Lewy bodies (DLB) are three clinically, genetically and neuropathologically overlapping neurodegenerative diseases collectively known as the Lewy body diseases (LBDs). A variety of molecular mechanisms have been implicated in PD pathogenesis, but the mechanisms underlying PDD and DLB remain largely unknown, a knowledge gap that presents an impediment to the discovery of disease-modifying therapies. Transcriptomic profiling can contribute to addressing this gap, but remains limited in the LBDs. Here, we applied paired bulk-tissue and single-nucleus RNA-sequencing to anterior cingulate cortex samples derived from 28 individuals, including healthy controls, PD, PDD and DLB cases (n = 7 per group), to transcriptomically profile the LBDs. Using this approach, we (i) found transcriptional alterations in multiple cell types across the LBDs; (ii) discovered evidence for widespread dysregulation of RNA splicing, particularly in PDD and DLB; (iii) identified potential splicing factors, with links to other dementia-related neurodegenerative diseases, coordinating this dysregulation; and (iv) identified transcriptomic commonalities and distinctions between the LBDs that inform understanding of the relationships between these three clinical disorders. Together, these findings have important implications for the design of RNA-targeted therapies for these diseases and highlight a potential molecular Ã¢Â€ÂœwindowÃ¢Â€Â of therapeutic opportunity between the initial onset of PD and subsequent development of Lewy body dementia.

| EGAS00001005305 | EGA

Synaptic phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein pathology

Project description:Lewy body inclusions enriched with aggregated forms of the presynaptic protein alpha-synuclein (aSyn) are a hallmark of synucleinopathy diseases such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB). To model this pathology, C57 mice were injected in the cortex or striatum with preformed fibrils (PFFs) prepared from mouse aSyn to induce the aggregation of the endogenous mouse protein. Monomeric aSyn was injected as a control. Aggregated aSyn was detected via immunohistochemical staining in the sensorimotor cortex at 1- and 3-months post-injection in PFF-injected mice, but not monomer-injected animals. Phosphoproteomics analysis was carried out on homogenates from the sensorimotor cortex of mice inoculated with PFFs or monomer, 3 months post-injection, and the data are presented here.

2024-11-25 | PXD058091 | Pride

Transcriptome profiling of prefrontal cortex (BA9) in neurodegenerative dementia using Affymetrix Human Transcriptome Array 2.0

Project description:We investigated transcriptome alterations in the prefrontal cortex (BA) of patients with Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) when compared with elderly controls without neurological or psychiatric diseases (CTRL) using Affymetrix Human Transcriptome Array 2.0 All brain samples were provided by the Brains for Dementia Research (BDR), UK. All cases were prospectively assessed by experienced clinicians using validated clinical rating instruments. The samples processed in each group were matched for age, sex and postmortem interval (PMI) as far as possible.

2021-05-24 | GSE150696 | GEO

Alzheimer’s Disease (AD) and Lewy Body Dementia (LBD): Detection of S-Nitrosylation in Key Proteins in Human, Post-mortem Brain Samples

Project description:FAD and Lewy Body Dementia (LBD): Detection of S-Nitrosylation in Key Proteins in Human, Post-mortem Brain Samples

2023-03-10 | PXD020945 | Pride

ATAC-seq studies to open chromatin acessible region of AD brain samples

Project description:We performed the ATAC-seq to brain tissue from prefrontal cortex region in 6 AD Postmortem samples and 6 control non-dementia postmortem samples.

2019-10-31 | GSE129040 | GEO

Brain transcriptomic analysis in Parkinson's disease patients stratified by Braak Lewy body stage / Sex differences in Parkinson's disease brain transcriptome

Project description:To investigate transcriptomic changes associated with Parkinson's disease development we compared frontal cortex gene expression across four Braak Lewy body stage groups. Additionally we investigated sex-specific gene expression differences in neuropathologically healthy donors and Parkinson's disease patients at Braak Lewy body stage 5. We investigated sex-specific gene expression differences in neuropathologically healthy donors and Parkinson's disease patients at Braak Lewy body stage 5.

2022-10-28 | GSE216281 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data